Document is current
Any future updates will be listed below
-
Authors
Sit, Andrea https://orcid.org/0000-0003-3551-4004
Seresirikachorn, Kachorn https://orcid.org/0000-0002-0158-7638
Zhang, Alexander S.
Mangussi-Gomes, João
Kanjanawasee, Dichapong https://orcid.org/0000-0003-2681-2958
Png, Lu Hui https://orcid.org/0000-0002-8440-5034
Kalish, Larry https://orcid.org/0000-0003-0227-8295
Campbell, Raewyn G. https://orcid.org/0000-0002-6512-3613
Alvarado, Raquel https://orcid.org/0000-0001-7250-2200
Harvey, Richard J. https://orcid.org/0000-0002-6942-8975
- License Information
-
More Information
Article History
Received: 8 May 2023
Accepted: 27 June 2023
First Online: 7 July 2023
Declarations
:
: Richard J. Harvey is consultant/advisory board with Medtronic, Novartis, Glaxo-Smith-Kline and Meda pharmaceuticals. He has been on the speakers' bureau for Glaxo-Smith-Kline, Astra-zeneca, Meda Pharmaceuticals and Seqirus. Larry Kalish is on the speakers' bureau for Mylan and Seqirus Pharmaceuticals. Raewyn G. Campbell is on the speakers' burea for Medtronic, Seqirus, GSK and Viatris. All other authors have no personal, financial, or institutional interest in any drugs, materials, or devices described in this article.
: This study received ethics approval from the St. Vincent's Hospital Research Ethics Committee (2019/PID13822).
